lansoprazole brands
6 registered brands containing lansoprazole in Zimbabwe.
Lansoprazole
PubChem CID 3883Molecular formula: C16H14F3N3O2S
As a PPI, lansoprazole is a prodrug and requires protonation via an acidic environment to become activated. Once protonated, lansoprazole is able to react with cysteine residues, specifically Cys813 and Cys321, on parietal H+,K+-ATPase resulting in stable disulfides. PPI's in general are able to provide prolonged inhibition of acid secretion due to their ability to bind covalently to their targets. Lansoprazole is a selective and irreversible proton pump inhibitor. In the acidic environment of the gastric parietal cell, lansoprazole is converted to active sulphenamide derivatives that bind to the sulfhydryl group of (H+, K+)-adenosine triphosphatase ((H+,K+)-ATPase), also known as the proton pump (H+,K+)-ATPase catalyzes the final step in the gastric acid secretion pathway. Lansoprazole's inhibition of (H+,K+)-ATPase results in inhibition of both centrally and peripherally mediated gastric acid secretion. The inhibitory effect is dose-related. Lansoprazole inhibits both basal and stimulated gastric acid secretion regardless of the stimulus.
Source: PubChem (NCBI) ยท compound 3883
| Product | Manufacturer | Status | Country |
|---|---|---|---|
| HELIGO 500 TABLET, COATED; ORAL |
Intas Pharmaceuticals | PRESCRIPTION PREPARATIONS 9TH SCHEDULE, (P.P.) | Zimbabwe |
| LAN-30 TABLET, COATED; ORAL |
Intas Pharmaceuticals | PHARMACIST INITIATED MEDICINES, (P.I.M.) | Zimbabwe |
| LANSA 15 CAPSULE; ORAL |
Inventia Healthcare | PHARMACIST INITIATED MEDICINES, (P.I.M.) | Zimbabwe |
| LANSA 30 CAPSULE; ORAL |
Inventia Healthcare | PHARMACIST INITIATED MEDICINES, (P.I.M.) | Zimbabwe |
| RELANSO CAPSULE; ORAL |
Inventia Healthcare Pvt Ltd, F1-f1/1-f75/1, Additional Ambernath Midc | PHARMACIST INITIATED MEDICINES, (P.I.M.) | Zimbabwe |
| RELANSO CAPSULE; ORAL |
Inventia Healthcare Pvt Ltd, F1-f1/1-f75/1, Additional Ambernath Midc | PHARMACIST INITIATED MEDICINES, (P.I.M.) | Zimbabwe |